Latest Content

Cencora's Brent Wilhelm on how specialty drug growth, cold chain demand, and reimbursement pressure are pushing distributors toward centralized safety stock and AI-driven flexibility.

Amy Niles of the Patient Advocate Foundation on Medicaid work requirements, ACA subsidy expiration and patient affordability in 2026.

In this week's Pharma Pulse, Cardinal Health expands its at-Home Solutions business with two acquisitions, President Trump lays out a phased tariff schedule for generic drugs, and Novo Nordisk sues Eli Lilly over GLP-1 advertising claims.

A subtraction-oriented approach to pharmacy data can surface avoidable drug waste that fragmented systems routinely miss.

Amy Niles of the Patient Advocate Foundation revisits her 2026 outlook on prior authorization reform and the Medicare Prescription Payment Plan.

Novo Nordisk’s complaint argues that Lilly's campaigns leave out information about the most effective injectable doses of Wegovy (semaglutide) and Ozempic (semaglutide), a dispute that could reshape how both companies compete for share in the GLP-1 market.

Ramarketing CEO Emma Banks revisits her "year of two halves" outlook, discussing whether 2026 has followed the same pattern and what she expects for H2.

Doceree launched Semmelweis, an AI model built for pharma commercialization, as drugmakers ramp up AI investment in marketing and sales operations.

Cencora's Brent Wilhelm explains why final-mile drug delivery hinges on carrier network visibility, and how AI is helping route around weather-driven disruptions.

Episode 1 of Supply Chain Signal breaks down the FDA's PreCheck pilot, the US Section 301 probe into German drug pricing, and CMS's move to make Medicare drug price negotiation permanent.

Brent Wilhelm of Cencora discusses why available inventory still leads to shortages, and how tighter distributor-manufacturer integration and AI could close the gap.

PwC's Roel van den Akker says pharma M&A ran beyond expectations in the first half of 2026, with dealmaking potentially on pace to hit $300 billion in H2.

Eli Lilly's acquisition of AtaiBeckley signals growing pharmaceutical industry commitment to psychedelic-based treatments for treatment-resistant depression.